All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View MPN content recommended for you
Real-world momelotinib in myelofibrosis: A multicenter Italian study
Results from a retrospective, multicenter, Italian study evaluating momelotinib safety and efficacy in patients with myelofibrosis (MF) and anemia (N = 39), including those with prior exposure to Janus kinase inhibitors (JAKi), were recently published in the European Journal of Haematology by Martorelli et al.
Key data: Overall response rates (ORRs) in patients with transfusion dependence and independence were 56% and 46%, respectively. At Week 24, hemoglobin increase >1.5 g/dL was observed in 26% of patients, constitutional symptom improvement in 51% of patients, and spleen volume reduction (SVR) >35% in 28% of patients.
Key learning: Momelotinib demonstrated substantial clinical activity in real-world patients with MF and anemia, including those previously treated with other JAKi, supporting its use in clinical practice.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
A 68-year-old male with primary myelofibrosis received ruxolitinib 10 mg twice daily for 7 months. His spleen size and symptoms are controlled, but Hb remains <8 g/dL. EPO, 210 mU/mL; platelets, 85,000/µL. What is your next step?
